Risk Factors Update Summary
- Addition of detailed risks related to General Data Protection Regulation (GDPR) compliance in the European Economic Area.
- Phase 2b clinical trial results for MN-166 in alcohol use disorder were presented, showing no superiority to placebo.
- Increased exposure to fines up to €20 million or 4% of total worldwide annual revenue for GDPR non-compliance.
- Phase 2 clinical trial results for MN-166 in glioblastoma were presented, including preclinical study data.
- Potential adverse impact from inflation on business operations, financial position, and liquidity.
- MN-166 high dose showed significant improvement in lung function in a chlorine gas-induced lung injury model.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1226616&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.